Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 92
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
Year : 2016  |  Volume : 5  |  Issue : 1  |  Page : 22-26

Omega-3 and Zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder

1 Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran
2 Department of Epidemiology and Biostatistics, Neurology and Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran
3 Department of Pediatric, Iran University of Medical Sciences, Tehran, Iran
4 Department of Anesthesiology, Arak University of Medical Sciences, Arak, Iran
5 Department of Pediatric, Arak University of Medical Sciences, Arak, Iran

Correspondence Address:
Fatemeh Dorreh
Department of Pediatric, Arak University of Medical Sciences, Arak
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2279-042X.176561

Rights and Permissions

Objective: The aim of this study is to evaluate the effect of zinc and omega-3 supplements as adjunctive drugs in the treatment of attention-deficit/hyperactivity disorder (ADHD) of children. Methods: This study is a randomized, double-blind clinical trial conducted on 150 children aged 6–15 years old that diagnosed as new cases of ADHD. Study subjects were evaluated for 8 weeks. Besides of drug of choice (methylphenidate) for the ADHD, patients received placebo in the control group (n = 50), zinc sulfate in second group (n = 50), and omega-3 (n = 50) in third group. Clinical improvement was checking by Conners' Parent and Teacher Rating Scales before and in 2nd, 4th, and 8th week of treatment. Results were analyzed with SPSS version 16 software. Findings: In this study, mean scores of Conners' scale showed significant improvement during treatment in the zinc group compared to control group in children that affected to attention-deficit disorder subtype of ADHD (P = 0.02). Moreover, in omega-3 group, better clinical response was seen than other groups (P < 0.05). However, there was no significant difference between omega-3 group compared to placebo group in the mean scores of Conners' scale (P = 0.89). Conclusion: Zinc supplementation accompanied by the main treatment significantly improves symptom of attention-deficit disorder subtype of ADHD. However, omega-3 supplementation was superior to zinc and placebo in the clinical improvement of ADHD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded519    
    Comments [Add]    
    Cited by others 7    

Recommend this journal